

Vimpat - (100MG ; 150MG ; 200MG ; 50MG Tablet)

| | | | |
|------------------------------|----------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | LACOSAMIDE | Innovator | UCB pharma |
| Dosage | 100MG ; 150MG ; 200MG ; 50MG Tablet | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | More Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | Less Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | VIMPAT is indicated in patients 17 years and older with partial-onset seizures as monotherapy or adjunctive therapy. | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Vimpat - (200 mg/ 20 ml; Intravenous, Solution)

| | | | |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | LACOSAMIDE | Innovator | UCB pharma |
| Dosage | 200 mg/ 20 ml; Intravenous, Solution | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | Less Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | None |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | VIMPAT is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older). | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Vimpat - (10mg/ml; Oral Solution)

| | | | |
|------------------------------|------------------------------------------------------------------------------------------------------|-----------------------------|---------------------|
| Generic Name | LACOSAMIDE | Innovator | UCB pharma |
| Dosage | 10mg/ml; Oral Solution | Branded US Sales | Less Than \$1000 mn |
| Probable FTF | Less Than 5 | Known Para IV Filers | More Than 5 |
| Other ANDA developers | More Than 5 | Tentative Approvals | Less Than 5 |
| Final Approvals | More Than 5 | Generic Launches | More Than 5 |
| Indication | VIMPAT is indicated for the treatment of partial-onset seizures in patients 4 years of age and older | | |
| Complexities | Yes | | |

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.